
GLPG
Healthcare · Biotechnology · $1.86B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now · -2328.6% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 30, 2026 | Time not confirmed | -0.09 | 0.21 | +327.5% |
| Mar 26, 2026 | After the close | -0.07 | 12.27 | +17628.6% |
| Nov 5, 2025 | After the close | -0.28 | -0.18 | +35.7% |
| Jul 23, 2025 | After the close | -0.13 | -0.93 | -615.4% |
| Apr 23, 2025 | After the close | -0.18 | 0.97 | +638.9% |
| Feb 12, 2025 | Time not confirmed | 0.28 | 0.30 | +8.0% |
| Oct 30, 2024 | After the close | -0.12 | -0.74 | -516.7% |
| Aug 1, 2024 | After the close | -0.02 | 0.07 | +450.0% |
| May 2, 2024 | After the close | -0.13 | 0.36 | +376.9% |
| Feb 22, 2024 | After the close | -1.18 | 2.39 | +302.5% |
| Nov 2, 2023 | After the close | -0.85 | 0.39 | +145.9% |
| Aug 3, 2023 | After the close | -0.37 | 0.08 | +121.6% |
| May 4, 2023 | After the close | -0.39 |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma;…
| 0.35 |
| +189.7% |
| Feb 23, 2023 | After the close | -0.64 | -3.16 | -393.8% |
| Nov 7, 2022 | Before the open | -1.24 | -0.54 | +56.5% |
| Aug 8, 2022 | After the close | -0.22 | -0.29 | -31.8% |
| May 5, 2022 | After the close | -0.77 | -0.20 | +74.0% |
| Feb 23, 2022 | After the close | -1.14 | 0.57 | +150.0% |
| Nov 4, 2021 | After the close | -1.23 | -0.98 | +20.3% |
| Aug 5, 2021 | After the close | -1.00 | -0.99 | +1.0% |
| May 6, 2021 | After the close | -1.10 | 0.14 | +112.7% |
| Feb 18, 2021 | After the close | -0.81 | -0.84 | -3.7% |
| Nov 5, 2020 | After the close | -0.85 | -1.45 | -70.6% |
| Aug 6, 2020 | After the close | -0.93 | -1.75 | -88.2% |
| May 6, 2020 | After the close | -0.65 | -0.78 | -20.0% |
| Mar 27, 2020 | After the close | -0.72 | -1.39 | -93.1% |
| Oct 24, 2019 | After the close | 2.47 | 8.13 | +229.1% |
| Jul 25, 2019 | After the close | -0.96 | -0.87 | +9.4% |
| Apr 25, 2019 | After the close | -1.09 | -0.89 | +18.3% |
| Feb 21, 2019 | Before the open | -0.63 | 0.27 | +142.9% |
| Oct 25, 2018 | After the close | -1.00 | 0.28 | +128.0% |
| Aug 3, 2018 | Before the open | -0.84 | -0.42 | +50.0% |
| Apr 26, 2018 | Before the open | -0.91 | -0.73 | +19.8% |
| Feb 23, 2018 | Before the open | -0.63 | -0.59 | +6.3% |